WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN

Aim. To compare effectiveness of non-drug therapy together with menopausal hormonal therapy (MHT) — estradiol hemihydrate 1 mg/drospirenon 2 mg (Angeliq® Bayer Pharma AG (Germany)) related to normalization of anthropometric and metabolic parameters, elasticity values and vascular age in women with metabolic syndrome (MS) in postmenopause.

Material and methods. The open-label prospective comparative controlled randomized study in 2 parallel groups. Sixty female patients (mean age 55,26±5,63 y.) with MS (according to IDF 2005 criteria) were randomized equally 1:1 into 2 groups. During 36 weeks patients of 1st group (n=30) received life style modification recommendations and monotherapy by Angeliq® , patients from 2nd group (controls, n=30) only followed life style modification. Groups were comparable by baseline clinical and demographic parameters. All patients received instructions for diet, physical activity and life style changes. Anthropometric, metabolic and instrumental assessments were done at baseline, in 12 and 36 weeks of therapy.

Results. Prescription of MHT in MS patients in postmenopause led to body weight decrease, decrease of percent composition of visceral fat, improvement of metabolic parameters, vascular elasticity and decrease of vascular age. There were no adverse events related to the drug during the study.

Conclusion. Angeliq® is effective and safe medication for low-dosage continuous combination MHT in menopausal MS that facilitates improvement of anthropometric parameters, vascular elasticity and vascular ageing.

1. Сметник В. П. Гормональная коррекция системных изменений в менопаузе М.: “МИК” и “Агар”, 2013. с. 14. Russian (Smetnik VP. Hormonal correction of systemic changes in menopause M.: “MIC” and “Agar”, 2013. p.14)

2. Zaydieva YaZ, et al. Hormone therapy in menopause: recommendations for clinical practice. Gynecology 2011; 13, 3: 8-12. Russian (Зайдиева Я.З. и др. Гормональная терапия в климактерии: рекомендации для клинической практики. Гинекология 2011; 13, 3: 8-12).

3. Poryvkina ON, Adasheva TV, Zadionchenko VS, et al. Efficacy and safety of hormone replacement therapy in patients with metabolic syndrome in postmenopausal. Cardiovascular Therapy and Prevention 2009; 8: 75-80. Russian (Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность заместительной гормональной терапии у пациенток с метаболическим синдромом в постменопаузе. Кардиоваскулярная терапия и профилактика 2009; 8: 75-80).

4. Kislyak OA, Starodubova AV. Arterial hypertension in postmenopausal women. Consilium medicum 2007; 9: 21-26. Russian (Кисляк О.А., Стародубова А.В. Артериальная гипертензия у женщин в постменопаузальном периоде. Consilium medicum 2007; 9: 21-26).

5. Mychka VB, Shchernakova YV, Masenko VP , et al. Current approaches to the treatment of metabolic syndrome. Consilium medicum 2009; 11, 5: 43-8. Russian (Мычка В.Б., Жернакова Ю.В., Масенко В.П. и др. Современные подходы к лечению метаболического синдрома. Consilium medicum 2009; 11, 5: 43-8).

6. Podzolkov VI, Osadchy KK, et al. Treatment of arterial hypertension in menopausal metabolic syndrome: whether there is left to β-blockers. Consilium medicum 2008; 10, 11: 5-11. Russian (Подзолков В.И., Осадчий К.К. и др. Лечение артериальной гипертензии при менопаузальном метаболическом синдроме: осталось ли место для β-адреноблокаторов. Consilium medicum 2008; 10, 11: 5-1).

7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J.A.M.A. 2007; 297: 1465-77.

8. Archer DF. et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause 2014; 21, 3: 227-235.

9. Chazova, IE, Balan VE, Mychka VB, et al. Keeping women with cardiovascular risk in peri- and postmenopausal women: Consensus Russian cardiologists and gynecologists. Systemic hypertension 2008; 3: 26-39. Russian (Чазова, И. Е., Балан В.Е., Мычка В.Б. и др. Ведение женщин с сердечно-сосудистым риском в пери-и постменопаузе: консенсус российских кардиологов и гинекологов. Системные гипертензии 2008; 3: 26-39).

10. Mychka VB. Current treatment options for patients with metabolic syndrome, the focus on the endothelium. Russian Journal of Cardiology 2014; 3: 107-113. Russian (Мычка В.Б. Современные возможности лечения больных с метаболическим синдромом — фокус на эндотелий. Российский кардиологический журнал 2014; 3: 107-13).

11. Innes KE, Selfe TK, Taylor AG. Menopause, the metabolic syndrome, and mind-body therapies. Menopause (New York, NY) 2008; 15, 5: 1005.

12. Stanczyk FZ, Hapgood, JP, Winer S, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine reviews 2012; 34, 2: 171-208.

13. Allender S, Scarborough P, Peto V, et al. European cardiovascular disease statistics. Department of Public Health, University of Oxford, 2008. p. 112.

14. Papakonstantinou NA, Stamou, MI, Baikoussis, NG, et al. Sex differentiation with regard to coronary artery disease. Journal of cardiology 2013; 62, 1: 4-11.

15. De Franciscis P, Mainini G, Labriola D, et al. Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome. Clin. Exp. Obstet. Gynecol. 2013; 40, 2: 233-5.

16. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010; 31,19: 2351-8.